论文部分内容阅读
NIFEVIROC,a small molecular compound,is a proprietary drug candidate which is developed by TARGETDRUG and holds great promise in inhibiting HIV-1 replication in infected paitents.Preclinical studies suggested that NIFEVIROC is a specific CCR5 antagonist determined by multiple receptor functional assays.In addition,NIFEVIROC demomtrated potent inhibition activity against HIV-1 entry into the target cells by effectively blocking the human CCR5 receptors on the cell membrane.Furthermore,NIFEVIROC showed strong antiviral activity against wide variety of HIV strains,including those multi-drug resistant mutants.Pharmaco "kinetic studies confirmed the oral bioavailability of NIFEVIROC,and its safety in various animal models in both acute and chronic states.